Alpaydin Baslo Sezin, Yuksel Burcu, Baytekin Isil, Incesoy Araz Ceren, Kara Eda Salihoglu, Koseoglu Mesrure, Teker Serap, Cengizler Begum, Oktelik Fatma Betul, Sen Aysu, Atakli Dilek, Deniz Gunnur, Soysal Aysun
University of Health Sciences, Bakirkoy Prof. Dr. Mazhar Osman Training and Research Hospital for Psychiatric, Neurologic, and Neurosurgical Diseases, Department of Neurology, Istanbul, Turkey.
University of Health Sciences, Bakirkoy Prof. Dr. Mazhar Osman Training and Research Hospital for Psychiatric, Neurologic, and Neurosurgical Diseases, Department of Infectious Diseases and Clinical Microbiology, Istanbul, Turkey.
Ideggyogy Sz. 2025 Mar 30;78(3-04):136-144. doi: 10.18071/isz.77.0136.
High titers of anti-SARS-CoV-2 immunoglobulin G (IgG) have been reported in cerebrospinal fluid (CSF) samples of patients with COVID-19, but the data are limited. Our purpose is to report the clinical features and CSF findings of patients with neurologic symptoms in the pandemic era, and to discuss the origin and importance of anti-SARS-CoV-2 IgG in CSF.
The data of 100 patients hospitalized in neurology inpatient clinics and tested for anti-SARS-CoV-2 IgG antibodies in CSF samples, between May 2021 and March 2022, were evaluated in a retrospective manner. Demographic features, presence of coronavirus disease 2019 (COVID-19) and/or COVID-19 history, vaccination, vaccine type, and neurologic diagnoses were noted. CSF and serum anti-SARS-CoV-2 antibody ratio (AR) were assessed using a Euroimmun ELISA assay. CSF cytology, CSF protein level, oligoclonal band, IgG index, and albumin quotient (QAlb) were analyzed and compared between CSF AR positive and negative groups.
QAlb and CSF protein levels were higher in the CSF anti-SARS-CoV-2 AR-positive group compared with CSF anti-SARS-CoV-2 AR-negative group (p.
Anti-SARS-CoV-2 antibodies in CSF seem to be related to a past immunization or a pre-existing cross reactive immunity and passive diffusion through a disrupted blood-brain-barrier, but not to an intrathecal antibody synthesis.
在新型冠状病毒肺炎（COVID-19）患者的脑脊液（CSF）样本中已报告有高滴度的抗严重急性呼吸综合征冠状病毒2（SARS-CoV-2）免疫球蛋白G（IgG），但数据有限。我们的目的是报告大流行时代有神经系统症状患者的临床特征和脑脊液检查结果，并讨论脑脊液中抗SARS-CoV-2 IgG的来源及重要性。
对2021年5月至2022年3月期间在神经内科住院病房住院并检测脑脊液样本中抗SARS-CoV-2 IgG抗体的100例患者的数据进行回顾性评估。记录人口统计学特征、2019冠状病毒病（COVID-19）和/或COVID-19病史、疫苗接种情况、疫苗类型和神经系统诊断。使用欧蒙酶联免疫吸附测定法评估脑脊液和血清抗SARS-CoV-2抗体比值（AR）。分析并比较脑脊液AR阳性和阴性组之间的脑脊液细胞学、脑脊液蛋白水平、寡克隆带、IgG指数和白蛋白商（QAlb）。
与脑脊液抗SARS-CoV-2 AR阴性组相比，脑脊液抗SARS-CoV-2 AR阳性组的QAlb和脑脊液蛋白水平更高（p。
脑脊液中的抗SARS-CoV-2抗体似乎与既往免疫接种或预先存在的交叉反应性免疫以及通过破坏的血脑屏障的被动扩散有关，而与鞘内抗体合成无关。
